Guidelines for the management of primary biliary cirrhosis (Q56429943)

https://api.crossref.org/works/10.1111%2FHEPR.12270

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Primary biliary cirrhosis: a 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Simplified criteria for the diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The consequences of apoptosis in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Apotopes and the biliary specificity of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Familial primary biliary cirrhosis in Hiroshima

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genetic and familial considerations of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Immunization with a Xenobiotic 6-Bromohexanoate Bovine Serum Albumin Conjugate Induces Antimitochondrial Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Frequency of monosomy X in women with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genetic factors of susceptibility and of severity in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Update on the genetics and genomics of PBC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Genomic variants associated with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Natural history of early primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Characterization of antimitochondrial antibodies in health adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The natural history of PBC: has it changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Natural history of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Liver biopsy in primary biliary cirrhosis: clinicopathological data and stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Incidence of cancer in primary biliary cirrhosis: the Mayo experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Prognosis in primary biliary cirrhosis: model for decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Effect of bezafibrate in primary biliary cirrhosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Fenofibrate treatment in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

A prospective trial of colchicine for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Itch in primary biliary cirrhosis: a patients' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Lysophosphatidic acid is a potential mediator of cholestatic pruritus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

The molecular mechanism of cholestatic pruritus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Guidelines on the management of osteoporosis associated with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Conventional therapy of Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Optimal timing of liver transplantation for primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: predicting outcomes with natural history models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Management of primary biliary cirrhosis: from diagnosis to end-stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Living donor liver transplantation for primary biliary cirrhosis: retrospective analysis of 50 patients in a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12270